San Diego – September 16, 2016 – Cooley advised the underwriters on Xenon Pharmaceuticals’ $34.5 million follow-on offering of 4,600,000 common shares.
Xenon, which trades on The NASDAQ Global Market, is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own, and for larger market indications that it intends to partner with global pharmaceutical companies.
Jefferies, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.
Cooley previously advised the underwriters on Xenon’s IPO.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.